Rapport Therapeutics (RAPP) CEO awarded 428,000 stock options at $27.75

Rhea-AI Filing Summary

Rapport Therapeutics CEO Abraham Ceesay received a new stock option grant covering 428,000 shares of common stock. The option has an exercise price of $27.75 per share and was awarded on February 2, 2026. It was reported as a direct holding.

The shares underlying this option vest in forty-eight equal monthly installments following January 1, 2026, conditioned on Ceesay’s continued service with the company on each vesting date. After this grant, he beneficially owned 428,000 derivative securities in the form of stock options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ceesay Abraham

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	428,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 428,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ceesay Abraham

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.75	02/02/2026		A		428,000		(1)	02/02/2036	Common Stock	428,000	$0	428,000	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Troy Ignelzi, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Rapport Therapeutics (RAPP) disclose about Abraham Ceesay in this Form 4?

Rapport Therapeutics reported that CEO and director Abraham Ceesay was granted a stock option for 428,000 shares on February 2, 2026. The transaction is a direct holding and represents derivative securities tied to the company’s common stock.

How many stock options did the Rapport Therapeutics CEO receive?

Abraham Ceesay received a stock option covering 428,000 shares of Rapport Therapeutics common stock. This option grant was reported as a derivative security and resulted in beneficial ownership of 428,000 stock options following the transaction.

What is the exercise price of Abraham Ceesay’s Rapport Therapeutics stock option?

The exercise price of Abraham Ceesay’s stock option is $27.75 per share. This means he can purchase Rapport Therapeutics common stock at $27.75 for each of the 428,000 underlying shares, subject to vesting and the stated expiration date.

When do Abraham Ceesay’s Rapport Therapeutics stock options vest?

The shares underlying this option vest in forty-eight equal monthly installments following January 1, 2026. Vesting is conditioned on Abraham Ceesay’s continued service with Rapport Therapeutics on each applicable vesting date throughout the four-year period.

What is the expiration date of the stock option granted to the Rapport Therapeutics CEO?

The stock option granted to Abraham Ceesay expires on February 2, 2036. Until that expiration date, and subject to vesting, he may exercise the option to purchase Rapport Therapeutics common stock at the fixed $27.75 per-share exercise price.

Is Abraham Ceesay’s stock option grant at Rapport Therapeutics direct or indirect ownership?

The Form 4 identifies Abraham Ceesay’s ownership of the stock option as direct. There is no indication of an intermediary entity or indirect nature of ownership in the transaction details, and no footnote disclaiming beneficial ownership is provided.